Bavarian Nordic launches chikungunya vaccine trial for paediatric population
Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population aged two …
Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population aged two …
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and …
Novartis has reported positive outcomes from the multi-centre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan) in adults with paroxysmal …
The relationship between neurodegenerative conditions such as Alzheimer’s disease and late-life mood disorders (LLMDs), including late-life depression (LLD) and late-life …
Artificial intelligence (AI) is revolutionising clinical trials, offering ways to improve the consent process, but concerns regarding the complete reliability …
Merck & Co (MSD) has initiated the randomised MOBILIZE-1 Phase III trial to assess the immunogenicity, efficacy, and safety of …
A £29bn investment into the National Health System (NHS) is ‘substantial’, but reform of the system is essential to ‘fix …
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially …
ImmuneWalk Therapeutics has presented positive topline data from the single ascending dose (SAD) part of the randomised, first-in-human Phase I …
While encouraged by revised regulations aimed at boosting UK clinical studies, experts say busy schedules of NHS workers present a …
Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at …
Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis (PsA) at …
Against the backdrop of the recent US Food and Drug Administration’s (FDA) staff cuts and administrative realignment, understanding accelerated approval …
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV …
The UK’s National Health Service (NHS) is receiving a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current …